Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Kidney Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 8 active trials
17 drugs · 284 active trials
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Toripalimab | Phase 2 | Phase 2 | 7 | 3 | 0 | 10 | 0 | — | — | Apr 22, 2020 |
| Cemiplimab | Phase 2 | Phase 2 | 6 | 5 | 0 | 9 | 0 | — | — | Jun 19, 2018 |
| Fludarabine | Phase 2 | Phase 2 | 5 | 3 | 0 | 35 | 0 | — | — | 1999-02 |
| Paclitaxel | Phase 2 | Phase 2 | 4 | 3 | 0 | 11 | 0 | — | — | 1994-03 |
| Tislelizumab | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Apr 12, 2021 |
| Docetaxel | Phase 2 | Phase 2 | 3 | 2 | 0 | 9 | 0 | — | — | 1997-08 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | Jul 7, 2022 |
| Leucovorin | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | Jun 26, 2015 |
| Sintilimab | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | Jun 1, 2020 |
| Eribulin | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Jun 26, 2015 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Dec 10, 2019 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Lutetium (177lu) Vipivotide Tetraxetan | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 31, 2025 |
| Cediranib | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2005-12 |
| Topotecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 1992-10 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2010-10 |
| Ramucirumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-11 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Dec 22, 2015 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 5, 2019 |
| Oxaliplatin | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-12 |
| Aflibercept | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-12 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 27, 2011 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Sep 3, 2008 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 30, 2008 |
| Retifanlimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jan 9, 2019 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Dec 17, 2012 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-06 |
| 5-Aminolevulinic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 15, 2026 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 15, 2023 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 19, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Guadecitabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 19, 2017 |
| Ibuprofen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 15, 2023 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Obinutuzumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 6, 2021 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ruxolitinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 8, 2026 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.